AbdulJabbar, Khalid http://orcid.org/0000-0002-4411-4435
,
Raza, Shan E. Ahmed http://orcid.org/0000-0002-1097-1738
Rosenthal, Rachel
Jamal-Hanjani, Mariam
Veeriah, Selvaraju
Akarca, Ayse
Lund, Tom
Moore, David A.
Salgado, Roberto
Al Bakir, Maise
Zapata, Luis
Hiley, Crispin T.
Officer, Leah http://orcid.org/0000-0002-3690-2386
Sereno, Marco http://orcid.org/0000-0003-4573-9303
Smith, Claire Rachel http://orcid.org/0000-0002-6401-2014
Loi, Sherene http://orcid.org/0000-0001-6137-9171
Hackshaw, Allan
Marafioti, Teresa
Quezada, Sergio A. http://orcid.org/0000-0002-9763-1700
McGranahan, Nicholas http://orcid.org/0000-0001-9537-4045
Le Quesne, John
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Yuan, Yinyin http://orcid.org/0000-0002-8556-4707
Article History
Received: 13 December 2019
Accepted: 23 April 2020
First Online: 27 May 2020
Competing interests
: Y.Y. has received speaker’s bureau honoraria from Roche and consulted for Merck & Co., Inc. C.S. receives grant support from Pfizer, AstraZeneca, BMS, Roche-Ventana, Boehringer-Ingelheim and Ono Pharmaceutical. C.S. has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi and the Sarah Cannon Research Institute. C.S. is a shareholder of Apogen Biotechnologies, Epic Bioscience, GRAIL and has stock options in and is co-founder of Achilles Therapeutics. M.A.B. is a consultant for Achilles Therapeutics. S.L. receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer, Eli Lilly and Seattle Genetics. S.L. has acted as consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, BMS, Merck, AstraZeneca and Roche-Genentech. S.L. has acted as consultant (paid to her institution) to Aduro Biotech, Novartis and G1 Therapeutics. D.A.M. has received speaker’s fees from AstraZeneca. M.J.H. is a member of the Advisory Board for Achilles Therapeutics.